Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Typhoid Fever - Pipeline Review, H1 2019, provides an overview of the Typhoid Fever (Infectious Disease) pipeline landscape.
Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called Salmonella typhi (S. typhi). Symptoms include abdominal tenderness, agitation, chills, delirium, hallucinations, severe fatigue and weakness. Treatment includes antibiotics and supportive therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Typhoid Fever - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Typhoid Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Typhoid Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 1, 7, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Unknown stages comprises 1, 1 and 1 molecules, respectively.
Typhoid Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Typhoid Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Typhoid Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Typhoid Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Typhoid Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Typhoid Fever (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Typhoid Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Typhoid Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Typhoid Fever - Overview
Typhoid Fever - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Typhoid Fever - Therapeutics Assessment
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Typhoid Fever - Companies Involved in Therapeutics Development
Eubiologics Co Ltd
GlaxoSmithKline Plc
Indian Immunologicals Ltd
Ology Bioservices Inc
Prokarium Ltd
Protein Potential LLC
Sanofi Pasteur SA
Shantha Biotechnics Pvt Ltd
Walvax Biotechnology Co Ltd
Typhoid Fever - Drug Profiles
(paratyphoid (bivalent) + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(paratyphoid + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(rotavirus (virus like particle) + typhiod) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(shigella + typhoid) (Bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Streptococcal pneumonia + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EUC-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infectious disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Typhella - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vi-CRM197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ViCRM-197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Typhoid Fever - Dormant Projects
Typhoid Fever - Discontinued Products
Typhoid Fever - Product Development Milestones
Featured News & Press Releases
Oct 08, 2012: Typhim Vi - Typhoid Polysaccharide Vaccine - antigen levels below required specification
Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine
Jun 23, 2011: Sanofi Pasteur’s Typhim Vi Receives Prequalification From World Health Organization
Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine
Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine
Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study
Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Typhoid Fever, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Typhoid Fever - Pipeline by Eubiologics Co Ltd, H1 2019
Typhoid Fever - Pipeline by GlaxoSmithKline Plc, H1 2019
Typhoid Fever - Pipeline by Indian Immunologicals Ltd, H1 2019
Typhoid Fever - Pipeline by Ology Bioservices Inc, H1 2019
Typhoid Fever - Pipeline by Prokarium Ltd, H1 2019
Typhoid Fever - Pipeline by Protein Potential LLC, H1 2019
Typhoid Fever - Pipeline by Sanofi Pasteur SA, H1 2019
Typhoid Fever - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2019
Typhoid Fever - Pipeline by Walvax Biotechnology Co Ltd, H1 2019
Typhoid Fever - Dormant Projects, H1 2019
Typhoid Fever - Discontinued Products, H1 2019
List of Figures
Number of Products under Development for Typhoid Fever, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
